Role of annexin A1 in early diagnosis of lung cancer
Keywords:
lung cancer, BAL, annexin A1Abstract
Background: The prevalence of lung cancer has shown an increase over the last few years which cause both health and economic burden. The biopsy is the gold standard tool for disease diagnosis, but it is usually not accepted by the patients due to its invasive nature. The use of non-invasive biomarkers is now attaining a great interest in diagnosis. Aim of the work: Assess the role of Annexin A1 in bronchoalveolar lavage and serum in the early diagnosis of lung cancer. Patients and methods: This study included 39 patients into two groups; group A (cases with lung cancer) and group B (cases with non-malignant lung lesions). All subjects were submitted to history taking and thorough full physical examination and laboratory analysis. Bronchoalveolar lavage (BAL) was performed in the cases within the two groups. Both serum and BAL levels of annexin A1 were assed in all cases. Results: In the current study, the level of annexin A1 in the serum and BAL were statistically significantly higher in the malignant group as compared with the non-malignant group (P 0.001).
Downloads
References
Elakad O, Li Y, Gieser N, Yao S, Küffer S, Hinterthaner M, et al. Role of Annexin A1 in Squamous Cell Lung Cancer Progression. Dis Markers. 2021;2021:5520832.
Adjei A A. Lung cancer worldwide. Journal of Thoracic Oncology. 2019;14(6):956.
Friedlaender A, Banna G, Malapelle U, Pisapia P and Addeo A. Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today? Frontiers in oncology. 2019;9:166.
Jakubowska K, Naumnik W, Niklińska W and Chyczewska E. Clinical significance of HMGB-1 and TGF-β level in serum and BALF of advanced non-small cell lung cancer. Respiratory Carcinogenesis: Springer; 2015. p. 49-58.
Chen Z, Xu Z, Sun S, Yu Y, Lv D, Cao C, et al. TGF-β1, IL-6 and TNF-α in bronchoalveolar lavage fluid: Useful markers for lung cancer? Scientific reports. 2014;4(1):1-4.
Uribarri M, Hormaeche I, Zalacain R, Lopez-Vivanco G, Martinez A, Nagore D, et al. A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis. Journal of thoracic oncology. 2014;9(10):1504-12.
Wang H, Zhang X, Liu X, Liu K, Li Y and Xu H. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer. Journal of Cancer Research and Therapeutics. 2016;12(1):355.
Araújo T G, Mota S T S, Ferreira H S V, Ribeiro M A, Goulart L R and Vecchi L. Annexin A1 as a Regulator of Immune Response in Cancer. Cells. 2021;10(9):2245.
Ganesan T, Sinniah A, Ibrahim Z A, Chik Z and Alshawsh M A. Annexin A1: a bane or a boon in cancer? a systematic review. Molecules. 2020;25(16):3700.
Allen K L, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, et al. Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non–small-cell lung carcinoma and rodent tumor models. Plos one. 2020;15(6):e0234268.
Bai J, Liu Z, Liu J, Zhang S, Tian Y, Zhang Y, et al. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging (Albany NY). 2019;11(24):12452.
Oshi M, Tokumaru Y, Mukhopadhyay S, Yan L, Matsuyama R, Endo I, et al. Annexin A1 expression is associated with epithelial–mesenchymal transition (EMT), cell proliferation, prognosis, and drug response in pancreatic cancer. Cells. 2021;10(3):653.
S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, et al. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene. 2019;38(10):1717- 33.
Surman M, Kędracka-Krok S, Hoja-Łukowicz D, Jankowska U, Drożdż A, Stępień E Ł, et al. Mass spectrometry-based proteomic characterization of cutaneous melanoma ectosomes reveals the presence of cancer-related molecules. International journal of molecular sciences. 2020;21(8):2934.
Association W M. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191-4.
Wuyts W A, Dooms C and Verleden G M. The clinical utility of
bronchoalveolar lavage cellular analysis in interstitial lung disease. American journal of respiratory and critical care medicine. 2013;187(7):777-.
Biaoxue R, Xiguang C, Hua L, Tian F and Wenlong G. Increased level of annexin A1 in bronchoalveolar lavage fluid as a potential diagnostic indicator for lung cancer. The International Journal of Biological Markers. 2017;32(1):132-40.
Kumar A A, Chawla R and Kumar S A. Clinical and Radiological Profile of Lung Cancer–Data from Southwestern Part of India. Age (in years). 2019;50(25):20.0.
Sayed S S, Elkholy M, Ismail E M and Abdulkareem E S. Patterns of Presentation of Lung Cancer in Aswan University Hospital. The Egyptian Journal of Hospital Medicine. 2019;75(1):1932-6.
Quoix E and Lemarié E. Epidemiological novelties in lung cancer. Revue des maladies respiratoires. 2011;28(8):1048-58.
Alamoudi O S. Lung cancer at a university hospital in Saudi Arabia: a four-year prospective study of clinical, pathological, radiological, bronchoscopic, and biochemical parameters. Annals of Thoracic Medicine. 2010;5(1):30.
Maasdorp S D, Snyman C E, Prins M, Van Rooyen F C and Struwig M C. Clinical profile of patients diagnosed with primary lung cancer at the Pulmonology Division, Universitas Academic Hospital, Bloemfontein, 2010-2011. Southern African Journal of Epidemiology and Infection. 2013;28(4):233-9.
Rai D K, Kumar A, Kumar A, Kumar A and Thakur S. A clinico-radiological and pathological profile of lung cancer patients presented to All India Institute of Medical Sciences (Patna). Eastern Journal of Medical Sciences. 2017:8- 11.
Chapman A M, Sun K Y, Ruestow P, Cowan D M and Madl A K. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta- analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122-34.
Reddy K P, Kong C Y, Hyle E P, Baggett T P, Huang M, Parker R A, et al. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. JAMA internal medicine. 2017;177(11):1613- 21.
Khalil E M, Anwar M M and M.Abdelfattah S. Pattern of treatment and clinico-epidemiological analysis of 804 lung and pleura cancer patients treated in radiation oncology department, NCI-Egypt. Egyptian Journal of Chest Diseases and Tuberculosis. 2016;65(1):271-8.
Buccheri G and Ferrigno D. Lung cancer: clinical presentation and specialist referral time. European Respiratory Journal. 2004;24(6):898- 904.
Beckles M A, Spiro S G, Colice G L and Rudd R M. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003;123(1):97S-104S.
Patil S and Rujuta A. ‘Bronchoscopic Characterization of Lesions’: Significant impact on lung cancer diagnosis with use of Transbronchial needle aspiration (TBNA) in Comparison to conventional diagnostic techniques (CDTs). Clinical Cancer Investigation Journal. 2017;6(6):239-.
Gebremariam T H, Haisch D A, Fernandes H, Huluka D K, Binegdie A B, Woldegeorgis M A, et al. Clinical characteristics and molecular profiles of lung cancer in Ethiopia. JTO Clinical and Research Reports. 2021;2(7):100196.
Rawat J, Sindhwani G, Gaur D, Dua R and Saini S. Clinico- pathological profile of lung cancer in
Uttarakhand. Lung India: official organ of Indian Chest Society. 2009;26(3):74.
Shepl S S, Ganna S A, Hodeib H A and Abd El-Zaher A H. A study of diagnostic utility of annexin A1 in bronchoalveolar lavage fluid of patients with bronchogenic carcinoma. Tanta Medical Journal. 2021;49(3):182.
Rong B, Zhao C, Liu H, Ming Z, Cai X, Gao W, et al. Elevated serum annexin A1 as potential diagnostic marker for lung cancer: A retrospective case-control study. American journal of translational research. 2014;6:558-69.
Qiu J, Choi G, Li L, Wang H, Pitteri S J, Pereira-Faca S R, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. Journal of clinical oncology. 2008;26(31):5060.
Almatroodi S A, McDonald C F, Collins A L, Darby I A and Pouniotis D S. Quantitative proteomics of bronchoalveolar lavage fluid in lung adenocarcinoma. Cancer genomics & proteomics. 2015;12(1):39-48.
Fang Y, Guan X, Cai T, Long J, Wang H, Xie X, et al. Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro. Molecular Medicine Reports. 2016;13(5):3858-66.
V H Mak., etal., Value of washings and brushings at fibreoptic bronchoscopy in the diagnosis of lung cancer.1990; Thorax.May;45(5):373-6.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
